Class-I/II/IV HDAC inhibition by panobinostat has an immune-enhancing effect in HER2+ breast tumors, providing compelling evidence that HDAC inhibitors enable trastuzumab to trigger an NK cell-mediated response, thus eradicating trastuzumab-refractory HER2+ tumors.399. This evidence concerns the gene ERBB2 and breast neoplasm.